Literature DB >> 27686933

[Sarcopenia and frailty 2016 : Going separate ways].

J M Bauer1,2.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27686933     DOI： 10.1007/s00391-016-1137-7

Source DB:  PubMed          Journal:  Z Gerontol Geriatr        ISSN： 0948-6704            Impact factor:   1.281


× No keyword cloud information.
  16 in total

Review 1.  Myostatin and sarcopenia: opportunities and challenges - a mini-review.

Authors:  Thomas A White; Nathan K LeBrasseur
Journal:  Gerontology       Date:  2014-01-17       Impact factor: 5.140

2.  Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Authors:  Clemens Becker; Stephen R Lord; Stephanie A Studenski; Stuart J Warden; Roger A Fielding; Christopher P Recknor; Marc C Hochberg; Serge L Ferrari; Hubert Blain; Ellen F Binder; Yves Rolland; Serge Poiraudeau; Charles T Benson; Stephen L Myers; Leijun Hu; Qasim I Ahmad; Kelli R Pacuch; Elisa V Gomez; Olivier Benichou
Journal:  Lancet Diabetes Endocrinol       Date:  2015-10-27       Impact factor: 32.069

Review 3.  Frailty and exercise interventions : Evidence and barriers for exercise programs.

Authors:  E Freiberger; W Kemmler; M Siegrist; C Sieber
Journal:  Z Gerontol Geriatr       Date:  2016-09-21       Impact factor: 1.281

Review 4.  Technology-based measurements for screening, monitoring and preventing frailty.

Authors:  L Dasenbrock; A Heinks; M Schwenk; J M Bauer
Journal:  Z Gerontol Geriatr       Date:  2016-09-16       Impact factor: 1.281

5.  Frailty in older adults: evidence for a phenotype.

Authors:  L P Fried; C M Tangen; J Walston; A B Newman; C Hirsch; J Gottdiener; T Seeman; R Tracy; W J Kop; G Burke; M A McBurnie
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2001-03       Impact factor: 6.053

Review 6.  Sarcopenia--The search for emerging biomarkers.

Authors:  Alexander Kalinkovich; Gregory Livshits
Journal:  Ageing Res Rev       Date:  2015-05-08       Impact factor: 10.895

7.  Significance of frailty for predicting adverse clinical outcomes in different patient groups with specific medical conditions.

Authors:  Martin Ritt; Karl-Günter Gaßmann; Cornel Christian Sieber
Journal:  Z Gerontol Geriatr       Date:  2016-09-14       Impact factor: 1.281

8.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

9.  Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

Authors:  Craig Campbell; Hugh J McMillan; Jean K Mah; Mark Tarnopolsky; Kathryn Selby; Ty McClure; Dawn M Wilson; Matthew L Sherman; Diana Escolar; Kenneth M Attie
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

10.  Frailty consensus: a call to action.

Authors:  John E Morley; Bruno Vellas; G Abellan van Kan; Stefan D Anker; Juergen M Bauer; Roberto Bernabei; Matteo Cesari; W C Chumlea; Wolfram Doehner; Jonathan Evans; Linda P Fried; Jack M Guralnik; Paul R Katz; Theodore K Malmstrom; Roger J McCarter; Luis M Gutierrez Robledo; Ken Rockwood; Stephan von Haehling; Maurits F Vandewoude; Jeremy Walston
Journal:  J Am Med Dir Assoc       Date:  2013-06       Impact factor: 4.669
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.